Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber

Summary

The purpose of this study is to determine whether long-acting octreotide is safe and effective in the treatment of patients with Rendu-Osler-Weber (e.g. HHT). The study hypothesis is that octreotide is safe and will reduce transfusion requirements and endoscopy frequency in ROW patients with refractory anaemia due to bleeding gastrointestinal telangiectasias.

Timeline

Start

2016-10

Primary completion

2018-07

Completion

2018-10

Drugs

Indications